丹参酮ⅡA磺酸钠联合厄贝沙坦治疗高血压合并肾损伤的疗效及对血清PCX和PICP水平的影响

Sodium tanshinonⅡA silate sodium combined with irbesartan in the treatment of hypertension with renal damage and its effect on serum levels of PCX and PICP

目的探讨不同治疗方案对高血压合并肾损伤患者的疗效研究及对血清足细胞标志蛋白(PCX)和血清Ⅰ型前胶原羧基端肽(PICP)的影响。方法将我院接受治疗的100例高血压合并肾损伤患者随机分为A和B 2组,每组50例。A组为试验组,即用丹参酮ⅡA磺酸钠联合厄贝沙坦进行治疗;B组为对照组,即单用厄贝沙坦进行治疗,疗程均为28d。观察2组患者治疗前后收缩压、舒张压、24h尿蛋白定量、尿免疫球蛋白G(IgG)以及血清PCX和PICP水平的变化。结果在一个疗程后,A组与B组的收缩压、舒张压、24h尿蛋白定量、尿免疫球蛋白G(IgG)以及血清PCX和PICP水平均较治疗前低,且A组低于B组,差异有统计学意义。结论丹参酮ⅡA磺酸钠联合厄贝沙坦治疗有高血压的肾损伤患者具有良好的疗效,既改善了血管状态,又保护了肾脏,比单独使用厄贝沙坦的效果更好。

Objective To investigate the effect and the impact of different treatment,regimens in patients with hypertension and renal injury.Methods 100 cases from April 2012 to April 2014 in our hospital with hypertension and renal injury were randomly divided into A and B 2groups,50 cases each.Group A,the experimental group,were given sodium tanshinoneⅡA and irbesartan;Group B as the control group,only given irbesartan treatment.The course was 28 days.Before and after the treatment,the systolic and diastolic blood pressure,24 hurinary protein,urinary immunoglobulin G（IgG）and changes in serum levels of PCX and PICP were observed.Results After a course of treatment,the systolic blood,diastolic blood pressure,24 hurinary protein,urinary immunoglobulin（IgG）and serum PCX and PICP levels of group A were signifantly lower than that of group B.Conclusion Sodium tanshinonⅡA silate sodium combined with irbesartan treatment of renal impairment in patients with high blood pressure showed a good effect.The vascular status was improved,and the kidneys,protection was better than the effect of irbesartan alone.